Cagrilintide Api 1415456-99-3

Shengnuo Biotech is a "specialized, special and new" and national high-tech enterprise focusing on the field of peptides, and will be listed in 2021. As a leading enterprise in the field of peptide APIs in China, the company focuses on the research and development, production and technical services of peptide drugs, and has the ability of the whole industry chain from drug discovery to commercial production.

Core business and technical strength
The company has more than 50 large-scale production technologies for listed peptide drugs at home and abroad, with a single batch of APIs reaching kg, covering five major dosage form production lines such as injections, lyophilized powder injections, and solid preparations. Its core technologies include large-scale production of thiocyclic peptides and carbocyclic peptides and rapid synthesis of peptides, and has obtained a number of national invention patents. It has passed the GMP certification of China, the United States, South Korea, and Mexico, and has passed the US FDA review with "0 defects", demonstrating the international quality management level.
R&D team and innovation capabilities
The R&D team is composed of more than 450 professionals, and its core members have been deeply involved in the field of peptide drugs for more than 15 years, establishing industry-university-research cooperation with scientific research institutions such as Sichuan University and the Chinese Academy of Sciences, and establishing innovative R&D centers with Zhejiang University and other universities, focusing on cutting-edge technologies such as peptide AI design and cyclic peptide synthesis. As of 2024, the company has 25 invention patents (including 1 international patent) and a number of non-patented technologies, covering 15 peptide API varieties, of which 14 have obtained domestic production approval and 11 have passed the US DMF filing.
Industrial layout and qualification certification
The existing production capacity of Shengnuo Pharmaceutical covers multiple treatment fields such as immunity, cardiovascular, and diabetes, and the annual output value continues to expand. The company now has a modern industrial park of 120 acres, equipped with FDA-certified API workshops and state-certified preparation workshops, with an annual production capacity of more than 400 million tablets (granules) of peptide APIs and solid preparations. As one of the earliest enterprises in China to realize the industrialization and transformation of new peptide drugs, it has provided technology transformation services for well-known pharmaceutical companies such as Chengdu Diao and Harbin Pharmaceutical Group, and has carried out technical cooperation with India and other enterprises. With a strict quality management system, the company has become a CDMO partner of well-known pharmaceutical companies such as Suzhou Paige Biotech and Biotech Biotech, and has provided customized production services for more than 30 projects.